Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria
2007

Thiacetazone and Its Effect on Mycolic Acids in Mycobacteria

publication Evidence: moderate

Author Information

Author(s): Alahari Anuradha, Trivelli Xavier, Guérardel Yann, Dover Lynn G., Besra Gurdyal S., Sacchettini James C., Reynolds Robert C., Coxon Geoffrey D., Kremer Laurent

Primary Institution: Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Université de Montpellier II et I, Centre National de la Recherche Scientifique (CNRS), UMR 5235, Montpellier, France

Hypothesis

Does thiacetazone inhibit the cyclopropanation of mycolic acids in mycobacteria?

Conclusion

Thiacetazone inhibits the cyclopropanation of mycolic acids in mycobacteria, revealing CMASs as its cellular targets.

Supporting Evidence

  • Thiacetazone and its analogues were shown to inhibit mycolic acid cyclopropanation.
  • Significant changes in mycolic acid profiles were observed in treated mycobacterial strains.
  • Overexpression of CMAS genes partially reversed the effects of thiacetazone.

Takeaway

Thiacetazone is a drug that helps fight tuberculosis by stopping bacteria from making important parts of their cell walls.

Methodology

The study used thin layer chromatography, mass spectrometry, and NMR analyses to assess the effects of thiacetazone on mycolic acid synthesis.

Limitations

The study does not explore the effects of thiacetazone on all possible mycobacterial strains.

Digital Object Identifier (DOI)

10.1371/journal.pone.0001343

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication